newsfilter
← Latest News
GlobeNewswire·

Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update

- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic